Kong Y, Xu XC, Hong L. Arteriovenous thrombotic events in a patient with advanced lung cancer following bevacizumab plus chemotherapy: A case report. World J Clin Cases 2022; 10(19): 6507-6513 [PMID: 35979297 DOI: 10.12998/wjcc.v10.i19.6507]
Corresponding Author of This Article
Liang Hong, MD, PhD, Associate Chief Physician, Department of Oncology, The First People’s Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, No. 199 Shixin South Road, Xiaoshan District, Hangzhou 311200, Zhejiang Province, China. kongying1504@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 6, 2022; 10(19): 6507-6513 Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6507
Arteriovenous thrombotic events in a patient with advanced lung cancer following bevacizumab plus chemotherapy: A case report
Ying Kong, Xiao-Cheng Xu, Liang Hong
Ying Kong, Xiao-Cheng Xu, Liang Hong, Department of Oncology, The First People’s Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou 311200, Zhejiang Province, China
Author contributions: Kong Y and Hong L were the patient’s oncologists, reviewed the literature, and contributed to manuscript drafting; Hong L and Xu XC analyzed and interpreted the imaging findings; Kong Y, Xu XC, and Hong L were responsible for the revision of the manuscript for important intellectual content; and all authors issued final approval for the version to be submitted.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Liang Hong, MD, PhD, Associate Chief Physician, Department of Oncology, The First People’s Hospital of Xiaoshan District, Xiaoshan Affiliated Hospital of Wenzhou Medical University, No. 199 Shixin South Road, Xiaoshan District, Hangzhou 311200, Zhejiang Province, China. kongying1504@163.com
Received: August 8, 2021 Peer-review started: August 8, 2021 First decision: November 6, 2021 Revised: November 15, 2021 Accepted: May 5, 2022 Article in press: May 5, 2022 Published online: July 6, 2022
Core Tip
Core Tip: This report describes a middle-aged man with postoperative recurrence of non-small cell lung cancer who developed cerebral infarction and pulmonary embolism 6 mo after treatment with bevacizumab, which was given in combination with chemotherapy. Concurrent arteriovenous thrombosis is rarely reported in the literature. Bevacizumab in conjunction with chemotherapy may increase the risk of arteriovenous thromboembolism. As a result, patients who undergo treatment with angiogenesis inhibitors should be carefully selected, and close monitoring and timely interventions (such as low-molecular-weight heparin prophylactic anticoagulant therapy) are necessary in order to reduce the risk of arterial thromboembolism and venous thromboembolism.
